In a big move for patients who take blood pressure medication on a regular basis, FDA last week approved the first generic versions of 4 drugs that contain the blood pressure-lowering medication olmesartan medoxomil (Benicar, Daiichi Sankyo).
In a big move for patients who take blood pressure medication on a regular basis, FDA last week approved the first generic versions of 4 drugs that contain the blood pressure-lowering medication olmesartan medoxomil (Benicar, Daiichi Sankyo).
Related: Actavis gains final FDA approval for generic Subutex
Before its patent expired this year, Benicar was a lucrative drug for Daiichi Sankyo. Daiichi Sankyo also sells Benicar HCT, Azor and Tribenzor, a combination of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide.
Benicar had US sales of approximately $1 billion for the 12 months ending August 31, 2016, according to IMS Health, while Bencar HCT had US sales of approximately $805 million during the same time period.
Related: HSCA to FDA: Address backlog of generic drug applications
Now, Mylan Pharmaceuticals, Par Pharmaceutical, Torrent Pharmaceuticals, Teva Pharmaceuticals and Macleods Pharmaceuticals are launching generic versions of the 4 drugs. The hypertension drugs are available in several dosage forms, similar to their branded counterparts.
“'First generics' are just what they sound like-the first approval by FDA which permits a manufacturer to market a generic drug product in the United States. FDA considers first generics to be important to public health, and prioritizes review of these submissions,” the agency said on its web site.
Read more: Diabetes complications fuel rising costs
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More